US Food and Drug Administration (USFDA) has successfully completed inspection at Laurus Labs’ Unit 4 at Visakhapatnam, Andhra Pradesh, without any observations and no form 483 issued. The inspection was carried out from July 08, 2019-July 12, 2019.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
